Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT06297226 · RECRUITING
Trial details
- NCT number
- NCT06297226
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-21
- Primary completion
- 2027-06-30
- Enrollment
- 230
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.